(Q45072371)

English

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

scientific article published in October 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

based on heuristic

inferred from title

Gordon C. Jayson

11

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

author name string

A Clamp

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

M Adams

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

R Atkinson

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

E Boven

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

A H Calvert

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

A Cervantes

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

T Ganesan

7

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

J Lotz

8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

P Vasey

9

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

P Cheverton

10

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

114-119

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.047

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.06.047

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45072371&oldid=2064552960"